GSK Agrees to Buy Potential Blood Cancer Treatment for Up to $750 Million

MT newswire2026/09/15 07:34

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

03:34 AM EDT, 09/15/2026 (MT Newswires) -- GSK (GSK) agreed to acquire a potential multiple myeloma T cell-engager therapy from Chimagen Biosciences for up to $750 million, the company said Tuesday. The deal includes an up-front payment plus development and commercial milestone payouts, the drugmaker said. GSK plans to develop and commercialize the therapy, with phase 1 trials expected to begin next year, the company said. Such T cell-engagers have previously been effective in treating multiple myeloma despite tolerability challenges which Chimagen's therapy is designed to overcome, GSK said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to reports, there is a severe shortage of core components for semiconductor equipment in South Korea. Delivery cycles have generally doubled, and waiting times for some Japanese-made parts are as long as 40 months, with components unavailable even at a premium price. Japanese suppliers are cautious about expanding production capacity, resulting in serious delays that have impacted downstream businesses. Major construction projects like Samsung’s Pyeongtaek and SK Hynix’s Yongin face the risk of postponement, with AI chip expansion plans running into a “hard wall” in the supply chain.

华尔街见闻•2026/09/18 04:16

New Zealand Dollar steadies as softer US bond yields keep USD on the defensive

FXStreet•2026/09/18 04:15

Japanese stocks rise 1.83%, breaking through 65,000 points

格隆汇•2026/09/18 03:38